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FAMILIAL MEDITERRANEAN FEVER: A GENERAL REVIEW 
Abstract 
Familial Mediterranean Fever (FMF) is an autosomal recessive inherited disease, which is accompanied by 
recurrent attacks of fever and serositis. It can be distinguished into two types. Type 1, is associated with 
recurrent short episodes of inflammation and polyserositis; type 2, is characterized by the accumulation 
of serum amyloid A mainly in the kidney leading to amyloidosis. The etiology of this disease is due to 
mutations in the MEFV gene, which encodes the protein “pyrin”. These mutations cause the uncontrolled 
production of proinflammatory cytokines including interleukin 1. Genetic analysis is important to confirm 
the diagnosis in the patients. Colchicine is the drug of choice. However, some people are resistant to this 
drug. In such cases, newer biologic agents have used in the treatment of the disease. This review aims to 
discuss the most recent advances about FMF including the major symptoms, the diagnosis, the genetics 
and the management. 
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1. INTRODUCTION 
Familial Mediterranean Fever (FMF) is an autosomal recessive disease with a periodic 
autoinflammatory pattern that can be distinguished from PFAPA by a family history and a 
differential diagnosis (Jamilloux et al., 2017). This disorder is mainly affecting the populations from 
Mediterranean ancestry including Arabs, Turks, Armenians and Jews (Heller et al., 1958). Despite 
this common prevalence, it can also be found in populations of non-Mediterranean ancestry as some 
cases were reported in Japanese, Chinese and Korean people (Ben-Chetrit and Levy, 1998; Ben-
Chetrit and Touitou, 2009; Lee et al., 2016; Kimura et al., 2018). Although most commonly known 
as FMF, this disease appeared under various other names, the most used of which were: recurrent 
polyserositis, periodic peritonitis and periodic disease (Zadeh et al., 2011).  
It possesses two phenotypes leading to two types 1 and 2. FMF type 1 includes a variety of 
mild signs like inflammation, peritonitis, fever and pleuritis. FMF type 2 is more serious since it 
causes amyloidosis in an asymptomatic individual that affects mainly the kidney (Pras, 1998; Kone 
Paut et al., 2000; Dember, 2006; Ben-Chetrit and Backenroth, 2001). The main cause of this disease 
is a mutation in chromosome 16 attacking the MEFV gene (Ostring and Singh-Grewal, 2016). 
Proinflammatory cytokines related to these mutations including IL-1β and IL-18 are known to cause 
excess inflammation (Chae et al., 2006; Kim et al., 2015; Chae et al., 2011). Diagnosis depends on 
symptoms and it is based on molecular genetic testing and on multiple serum cytokine profiling 
(Zadeh et al., 2011; Koga et al., 2016). The mainstay of treatment is life-long colchicine drug given 
daily to reduce the symptoms of the disease (Goldfinger, 1972; Sönmez et al., 2016; Ozdogan and 
Ugurlu, 2019). Unfortunately, the use of this drug has been complicated by resistance in a minority 
of patients. Since carriers of FMF show significantly elevated levels of serum TNF alpha, IL-1, and 
IL-6, FMF patients with insufficient response to colchicine were successfully treated with anti IL-1, 
anti IL-6, or TNF inhibitors drugs. Therefore, it is best to use colchicine in combination with 
biologics such as anakinra and canakinumab (Belkhir et al., 2007; Grattagliano et al., 2014; 
Alghamdi, 2017; Ozdogan and Ugurlu, 2019; El Hasbani et al., 2019). Scientist’s discoveries 
concerning FMF throughout the years summarized in Table 1. 
 
2. SYMPTOMS OF FMF 
2.1. Common Symptoms 
Recurrent attacks of fever mainly during the early childhood (El Shanti et al., 2006). The 
duration of attacks is 1 to 3 days and the time between them is variable depending on the patients 
(Ostring and Singh-Grewal, 2016). 
 
a. Abdominal attacks  
About 95% of the patients experience abdominal pain. Physicians often report signs of 
rigidity of the abdominal muscles, abdominal distensions and rebound tenderness in patients 
suffering from FMF (Shohat and Halpern, 2010). 
 
 
Table 1: This table shows scientist’s discoveries concerning FMF throughout the years. 
Dates: Historical Events: Ref 
Second Century 
AD 
Galen described cyclic fever that he linked to different moon phases (Reimann, 1951) 
Past 200 yrs. Many authors described a syndrome associated with recurrent attacks of 
fever ,abdominal ,chest and joint pain  
(Adwan, 2015) 
1820 Colchicine was named by the French chemists Pellelier and Caventon  (Golfinger, 
1972) 
1908 Janeway and Mosenthal described a young girl with intermittent fever and 
abdominal pain that refer it to FMF instead of any other auto inflammatory 
syndrome  
(Janeway and 
Mosenthal,1908) 
1945 Siegal announced the first exact description of FMF which later appeared 
under various  other names including: Catten-Namou syndrome and 
periodic disease 
(Siegal, 1945) 
1948 Reimann who described the term periodic disease explained that many 
adjectives are used interchangeably before the noun indicating the 
outstanding characteristic 
(Reimann, 1948) 
1951 Two French physicians Cattan and Namou realized the association of FMF  
with renal disease 
(Cattan and 
Namou,1951) 
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Continue Table 1 
 
1958 -Tuqan at the American University of Beirut in Lebanon indicate the 
occurrence of amyloidosis 
-Heller et al confirm the genetic nature of the disease 
(Tuqan, 1958; 
Heller et al., 
1958) 
1972 Colchicine introduced as a prophylactic treatment in FMF which decreases 
the hazards of amyloidosis 
(Hartung, 1954) 
1974 The efficacy of colchicine confirmed through random controlled  trails (Goldstein and 
Schwabe, 1974; 
Zemer et al., 
1974) 
1976 Trails confirmed that colchicine acts by inhibiting leukocyte migration (Dinarello et al., 
1976) 
1997 Two distinct groups , American and French, identified the MEFV gene by 
positional cloning 
(The 
International 
FMF 
Consortium; 
French FMF 
Consortium) 
2002 Martinon et al detect a caspase-activating complex called "The 
Inflammasome" which give the basics for the exact molecular mechanisms 
in which pyrin participates in the disease process    
(Martinon et al., 
2002) 
2007 Papin et al detect that pyrin binds particular inflammasome components 
such as caspase-1 and interleukin-1B that was a great discovery to reveal 
the disease process at the molecular level   
(Papin et al., 
2007) 
 
 
b. Articular attacks: 
About 75% of the patients experience articular and joint pain. The three main manifestations 
are: an elevated fever in the first day, a bilateral fashion of attacks involving large joints of the leg 
and a gradual decrease in the symptoms after a peak in 24-48 hours (Shohat and Halpern, 2010). 
The attacks are commonly in the hip or knee but it can emerge to the ankle, shoulder, 
temporomandibular or sternoclavicular joints (Shohat and Halpern, 2011). As a result, arthritis, 
arthralgia and myalgia can occur (Ali et al., 2016). 
 
c. Pleuritis: 
Pleural attacks accompanied with high-peaking fever have been described in 10% of 
pediatric patients. Physical examination is nonspecific in young patients and is mainly characterized 
by unilateral chest pain that increases in inspiration, shortness of breath, febrile dyspnea and rapid 
shallow breathing (Tarantino et al., 2016). 
 
d. Pericarditis: 
Pericarditis is commonly seen with FMF, presenting usually as chest pain and an increase in 
ST segment of electrocardiogram. It is difficult to detect when accompanied with pleuritis (El 
Shanti et al., 2006; Okutur et al., 2008). Yet, massive pericardial effusions and cardiac tamponade 
have been reported requiring pericardiocentesis (Tunca et al., 2005; Ishak et al., 2006; Sanchez 
Ferrer et al., 2015). 
 
e. Amyloidosis: 
Amyloidosis is considered one of the powerful complications caused. It affects the kidney 
causing a large amyloid deposition in the tissues of this organ as abnormal, insoluble fibers. This 
accumulation results in nephrotic syndrome and it may lead to end-stage renal disease (ESRD) 
(Bilginer et al., 2011). Although the kidney is the most organ affected, serum amyloid A (SAA) can 
be accumulated in the gastrointestinal tract, the liver, the spleen, the thyroid and after a long period 
in the heart and testes as well (Ben-Chetrit and Levy, 1998; Lofty et al., 2016). The high risk of 
developing amyloidosis is when the patient does not have a rapid diagnosis after the disease onset 
and subsequently does not begin with the treatment (Cefle et al., 2005). Varan et al. showed that 
high CRP levels during the attack-free periods may be a strong risk factor for the development of 
amyloidosis in patients with FMF (Varan et al., 2019). 
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 f. Sleep disturbances: 
Poor sleep quality is common in adult FMF patients. Anxiety, depression and fatigue are 
more frequent in FMF patients than healthy individuals (Kucuksahin et al., 2017).  
Makay et al. showed that sleep quality was negatively affected by the number of attacks. 
Patients with a higher number of attacks were noted to struggle in falling asleep (Makay et al., 
2014). In fact, inflammation can contribute to mood disorders and sleep disturbance. 
 
2.2. Rare Symptoms 
In rare cases, the common symptoms are accompanied with protracted febrile myalgia, 
erysipelas-like erythema over the lower limbs, reduced fertility and vasculitides (Ostring and Singh-
Grewal, 2016; Shohat and Halpern, 2011). 
 
3. DIAGNOSIS OF FMF 
Since FMF usually requires lifelong treatment, it is important to establish a timely, correct 
diagnosis. During attacks, there is a huge influx of sterile poly-mononuclear leukocytes to affected 
sites in the body. Therefore, inflammatory serological studies indicate increase in acute phase 
reactants such as C-reactive protein, fibrinogen, erythrocytes-sedimentation rate and increased 
white blood cell count with neutrophilia (Zadeh et al., 2011). Occasionally, the presentation is less 
typical and, molecular genetic testing may be helpful (Sonmez et al., 2016; Soriano and Manna, 
2012). 
 
3.1. Molecular Genetic Testing 
Diagnostic molecular testing comprises different testing strategies (Booty et al., 
2009). Targeted molecular testing for the 12 most common MEFV mutations (E148Q, P369S, 
F379L, M680I (G/ C), M680I (G/A), I692del, M694V, M694I, K695R, V726A, A744S, and 
R761H). Example of Targeted Mutation Analysis: Familial Mediterranean fever strip assay. This 
particular assay is designed to detect the mutations by polymerase chain reaction and reverse 
hybridization (Ben-Chetrit and Touitou, 2009). Also, offering full sequence analysis of all the 
coding exons of the MEFV gene to assure accuracy (Zadeh et al., 2011). 
 
3.2. Multiple Serum Cytokine Profiling to Identify Combinational Diagnostic 
Biomarkers in Attacks of Familial Mediterranean fever 
Several studies showed that IL-6 increased in the serum during FMF attacks (Manukyan et 
al., 2008; Akcan et al., 2003; Gang et al., 1999). IL-6 is a main inflammatory cytokine and as a 
promising target in this disease. IL-1 signaling plays pathogenic roles in the development of auto 
inflammatory disease (Chung et al., 2009). On the other hand, IL-17 and IL-18 serum levels of FMF 
patients both in attack and in remission were significantly higher than those of healthy controls, as 
well as CXCL10, IL-12p40, and IFN-  in addition to sCD54 levels, but not significantly higher 
than the levels of patients in remission. Elevated serum levels of IL-10 along with pro-inflammatory 
cytokines were reported in FMF patients in attack (Manukyan et al., 2008).  
In addition, IL-12 serum level increased in patient in both remission and attacks (Ben-Zvi and 
Livneh, 2011; Erken et al., 2006). 
 
4. MOLECULAR AND GENETICS 
 There is a wide number of MEFV mutations linked with FMF. Across all FMF patients, 
nearly around 80% of MEFV mutations are accounted for by E148Q, M680I, M694I, M694V, and 
V726A. The percentages for the particular mutation in a single mutation cases differ by the 
population under study (Aslan, 2011). The studies also indicate that individuals with 1 MEFV 
mutation exhibit symptoms that are often less severe than individuals with 2 mutations, and they 
also show higher levels of other inflammation markers than individuals with no mutations. 
 Studies are beginning to appear in the literature that attempt to identify the reasons that the 
typically recessive MEFV mutation begins to behave as if dominant, thereby causing the clinical 
symptoms of FMF (Touitou, 2013). The body evidence is suggesting that the environmental and 
epigenetic sources are important in triggering disease expression in patients with a single mutation 
(Jeru et al., 2013).  
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 Recently, studies showed that a heterozygote state might also result in the disease. Mutations 
are located in MEFV as mentioned earlier and encode a protein called pyrin/marenostrin/TRIM20. 
Among more than 300 mutations in the MEFV gene are now the most common in classically 
affected populations. There are mutations in 6 of the 10 exon of the MEFV (1, 2,3,5,9, and 10), 
where the three hot spots mutations are on exon 2 and 10 (E148Q, E148V/ M694V, M694I, M694 
del/ M680I (G/C), M680 (G/A), M680L). There are 29 known mutations (26 missense, 1 nonsense, 
2 small deletions). Phenotypes ranges from mild (E148Q mutation is the mildest and least 
penetrant) to severe (genotype include 2 mutations in the gene codon 680 or 694) (Giaglis et al., 
2007). 
 
5. PYRIN PROTEIN 
5.1.  Pyrin Structure and Protein-protein Interaction 
MEFV gene encodes for the protein called pyrin. It is composed of an N-terminal RING 
domain, B-box domain and a C-terminal coiled-coil domain where most mutations are found 
(Manukyan and Aminov, 2016). There are several interactions between pyrin and many other 
proteins and oligomers, Figure 1. For example, the PYD domain interacts with an adapter protein 
called apoptosis-associated speck-like protein (Richards et al., 2001). 
 
Fig.1: Schematic outline of pyrin structure ((Rosalie Heilig and Petr Broz, 2018) 
 
5.2. Regulation of Innate Immunity by Pyrin 
Through the PYD domain, pyrin regulates IL-1β activation resulting in 
proinflammatory (Yu et al., 2006, Seshadri et al., 2007; Gavrilin et al., 2012) or anti-
inflammatory (Chae et al., 2006; Papin et al., 2007; Hesker et al., 2012) effects. Most of the 
studies suggest that the NALP3 inflammasome complex has a significant impact in the 
pathogenesis of FMF (Papin et al., 2007; Omenetti et al., 2014). 
 
5.3. Pyrin and Danger Signals 
A new interaction of pyrin with the adaptor protein PSTPIP1which regulates the 
cytoskeleton was confirmed by Waite et al (Waite et al., 2009). The correlation between pyrin 
and the cytoskeleton is confirmed by the efficiency of colchicine (Zemer et al., 1986). Table 2. 
Shows different drugs used in treatment of FMF. 
 
 
5.4. Roles of Pyrin 
Pyrin functions in inflammasome assembly (Vajjhala et al., 2014), by sensing 
intracellular danger signals (Kim et al., 2015; Dumas et al., 2014; Xu et al., 2014) and activation 
of mediators of inflammation by the inflammasome (IL-1β, IL-18) (Kim et al., 2015; Chae et al., 
2011). In addition, it plays a role in apoptosis (Richards et al., 2001; Martinon et al., 2001; 
Gumucio et al., 2002) in pyrin-cytoskeleton interactions (Waite et al., 2009) and in autophagy of 
innate immunity regulators (Kimura et al., 2015). 
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Table 2: Drugs used in the treatment of FMF. 
Different 
drugs 
Uses Ref 
Steroids or 
narcotics 
Provide temporary relief of pain before definitive diagnosis (Zadeh et al., 
2011) 
Nonsteroidal 
anti-
inflammatory  
drugs 
Treat fever and pain (Zadeh et al., 
2011) 
Etanercept, 
infliximab, 
or 
adalimumab 
Control FMF attacks such as chronic arthritis and sacroiliitis                                                                                    (Bilgen et al., 
2011) 
Anakinra Suppresses inflammation (Grattagliano et 
al., 2014) 
Colchicine The mainstay of treatment since 1972. It increases the quality of 
life and prevents the development of amyloidosis and the 
recurrence of febrile attacks 
(Goldfinger, 
1972; Sonmez et 
al., 2016; 
Ozdogan and 
Ugurlu, 2019) 
Tocilizumab Controls the signs related to the attacks, and prevents the 
development of AA amyloidosis 
(Ugurlu et al., 
2017; Migita et 
al., 2018) 
Canakinumab Improves renal functions, reduces attacks, decreases the level of 
high-level laboratory findings associated with FMF and is an 
effective therapy to patients who are resistant to colchicine 
(Yazilitas et al., 
2018; Berdeli et 
al., 2019) 
 
6. CONCLUSION   
 This monogenic disease continues to be of interest to clinical and basic researchers.  
 Experts have worked on compiling recommendations to guide physicians in the diagnosis, 
management, and treatment of FMF.  
 Colchicine is the drug mostly recommended, and IL1-blockade is recently being considered. 
Further, molecular investigation is required. 
 
ACKNOWLEDGEMENT 
 We would like to thank the students Wafaa BEQAI and Sara KARROUM for their 
participation. 
 
REFERENCES  
 Alghamdi, M., (2017). Familial Mediterranean fever, review of the literature. Clinical 
Rheumatology, 36(8): p. 1707-1713. 
 Adwan, M.H., (2015). A brief history of familial Mediterranean fever. Saudi Medical Journal, 
36(9): p. 1126-1127. 
 Ali, N.S., J.C. Sartori-Valinotti, and A.J. Bruce, (2016). Periodic fever, aphthous stomatitis, 
pharyngitis, and adenitis (PFAPA) syndrome. Clinics in Dermatology, 34(4): p. 482-486. 
 Akcan, Y., et al., (2003). The importance of serial measurements of cytokine levels for the 
evaluation of their role in pathogenesis in familial Mediterranean fever. European Journal of 
Medical Research, 8(7): p. 304-306. 
 Aslan, D. (2011). Familial Mediterranean fever with a single MEFV mutation: can a deletion 
resulting in alpha-thalassemia be the cause? Journal of Human Genetics, 56(2): p. 169-171. 
 Ben-Chetrit, E., & Levy, M. (1998). Familial Mediterranean fever. The Lancet, 351(9103), 659-
664. 
 Ben‐Chetrit, E., & Touitou, I. (2009). Familial Mediterranean fever in the world. Arthritis Care 
& Research, 61(10), 1447-1453. 
5
Houri et al.: FAMILIAL MEDITERRANEAN FEVER: A GENERAL REVIEW
Published by Digital Commons @ BAU, 2019
 Ben-Chetrit, E., & Backenroth, R. (2001). Amyloidosis induced, end stage renal disease in 
patients with familial Mediterranean fever is highly associated with point mutations in the MEFV 
gene. Annals of the rheumatic diseases, 60(2), 146-149. 
 Belkhir, R., et al., (2007). Treatment of familial Mediterranean fever with anakinra. Annals of 
Internal Medicine, 146(11): p. 825-826. 
 Bilginer, Y., T. Akpolat, and S. Ozen, (2011). Renal amyloidosis in children. Pediatric 
Nephrology, 26(8), 1215-27. 
 Booty, M.G., et al., (2009). Familial Mediterranean fever with a single MEFV mutation: where 
is the second hit? Arthritis & Rheumatism: Official Journal of the American College of 
Rheumatology, 60(6): p. 1851-61. 
 Ben-Zvi, I., & Livneh, A. (2011). Chronic inflammation in FMF: markers, risk factors, outcomes 
and therapy. Nature Reviews Rheumatology, 7(2), 105. 
 Bilgen, S.A., et al., (2011). Effects of anti-tumor necrosis factor agents for familial 
mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to 
colchicine treatment. JCR: Journal of Clinical Rheumatology, 17(7), 358-362. 
 Berdeli et al., (2019). Treatment of familial Mediterranean fever with canakinumab in patients 
who are unresponsive to colchicine. European journal of rheumatology, 6(2): 85-88.  
 Chae, J.J., et al., (2006). The B30.2 domain of pyrin, the familial Mediterranean fever protein, 
interacts directly with caspase-1 to modulate IL-1beta production. Proceedings of the National 
Academy of Sciences,103(26): p. 9982-9987. 
 Chae, J.J., et al., (2011). Gain-of-function Pyrin mutations induce NLRP3 protein-independent 
interleukin-1beta activation and severe autoinflammation in mice. Immunity, 34(5): p. 755-768. 
 Cattan, R., & Mamou, H. (1951). 14 Cases of periodic disease, 8 of which are complicated by 
kidney diseases. Bulletins et memoires de la Societe medicale des hopitaux de Paris, 67(25-26), 
1104-1107. 
 Cefle, A., et al., (2005). A comparison of clinical findings of familial Mediterranean fever 
patients with and without amyloidosis. Rheumatology International, 25(6): p. 442-446. 
 Chung, Y., et al., (2009). Critical regulation of early Th17 cell differentiation by interleukin-1 
signaling. Immunity, 30(4): p. 576-587. 
 Dember, L. M. (2006). Amyloidosis-associated kidney disease. Journal of the American Society 
of Nephrology, 17(12), 3458-3471. 
 Dinarello, C.A., et al., (1976). Effect of prophylactic colchicine therapy on leukocyte function in 
patients with familial Mediterranean fever. Arthritis & Rheumatism: Official Journal of the 
American College of Rheumatology, 19(3): p. 618-622. 
 Dumas, A., et al., (2014). The inflammasome pyrin contributes to pertussis toxin-induced IL-
1beta synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis. PLoS 
pathogens,  10(5). 
 El-Shanti, H., Majeed, H. A., & El-Khateeb, M. (2006). Familial mediterranean fever in 
Arabs. The Lancet, 367(9515), 1016-1024. 
 El Hasbani, G., Jawad, A., & Uthman, I. (2019). Update on the management of colchicine 
resistant Familial Mediterranean Fever (FMF). Orphanet Journal of Rare Diseases, 14(1), 224. 
 Erken, E., Ozer, H. T., & Gunesacar, R. (2006). Plasma interleukin-10 and interleukin-12 levels 
in patients with familial Mediterranean fever. Rheumatology international, 26(9), 862-864. 
 French, F. M. F. (1997). Consorcium. A candidate gene for Familial Mediterranean Fever. J Nat 
Genet, 17(1), 25-31. 
 Goldfinger, S. E. (1972). Colchicine for familial Mediterranean fever. The New England journal 
of medicine, 287(25), 1302. 
6
BAU Journal - Health and Wellbeing, Vol. 2, Iss. 1 [2019], Art. 5
https://digitalcommons.bau.edu.lb/hwbjournal/vol2/iss1/5
  Grattagliano, I., Bonfrate, L., Ruggiero, V., Scaccianoce, G., Palasciano, G., & Portincasa, P. 
(2014). Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to 
biologics. Clinical Pharmacology & Therapeutics, 95(1), 89-97. 
 Goldstein, R. C., & Schwabe, A. D. (1974). Prophylactic colchicine therapy in familial 
Mediterranean fever: a controlled, double-blind study. Annals of Internal Medicine, 81(6), 792-794. 
 Gang, N., Drenth, J. P., Langevitz, P., Zemer, D., Brezniak, N., Pras, M., & Livneh, A. (1999). 
Activation of the cytokine network in familial Mediterranean fever. The Journal of 
Rheumatology, 26(4), 890-897. 
 Giaglis, S., Papadopoulos, V., Kambas, K., Doumas, M., Tsironidou, V., Rafail, S., ... & Ritis, 
K. (2007). MEFV alterations and population genetics analysis in a large cohort of Greek patients 
with familial Mediterranean fever. Clinical genetics, 71(5), 458-467. 
 Gavrilin, M. A., Abdelaziz, D. H., Mostafa, M., Abdulrahman, B. A., Grandhi, J., Akhter, A., ... 
& Amer, A. O. (2012). Activation of the pyrin inflammasome by intracellular Burkholderia 
cenocepacia. The Journal of Immunology, 188(7), 3469-3477. 
 Gumucio, D. L., Diaz, A., Schaner, P., Richards, N., Babcock, C., Schaller, M., & Cesena, T. 
(2002). Fire and ICE: the role of pyrin domain-containing proteins in inflammation and 
apoptosis. Clinical and experimental rheumatology, 20(4; SUPP/26), S-45-53. 
 Heller, H., Sohar, E., & Sherf, L. (1958). Familial Mediterranean fever. AMA Archives of 
Internal Medicine, 102(1), 50-71. 
 Hartung, E. F. (1954). History of the use of colchicum and related medicaments in gout: with 
suggestions for further research. Annals of the rheumatic diseases, 13(3), 190-200. 
 Hesker, P. R., Nguyen, M., Kovarova, M., Ting, J. P. Y., & Koller, B. H. (2012). Genetic loss of 
murine pyrin, the Familial Mediterranean Fever protein, increases interleukin-1β levels. PloS 
one, 7(11). 
 Ishak, G. E., Khoury, N. J., Birjawi, G. A., El-Zein, Y. R., Naffaa, L. N., & Haddad, M. C. 
(2006). Imaging findings of familial Mediterranean fever. Clinical imaging, 30(3), 153-159. 
 Jamilloux, Y., Belot, A., Magnotti, F., Benezech, S., Gerfaud-Valentin, M., Bourdonnay, E., ... 
& Henry, T. (2018). Geoepidemiology and immunologic features of autoinflammatory diseases: a 
comprehensive review. Clinical reviews in allergy & immunology, 54(3), 454-479. 
 Janeway, T. C., & Mosenthal, H. O. (1908). An unusual paroxysmal syndrome, probably allied 
to recurrent vomiting: with a study of the nitrogen metabolism. Archives of Internal Medicine, 2(3), 
214-225. 
 Jéru, I., Hentgen, V., Cochet, E., Duquesnoy, P., Le Borgne, G., Grimprel, E., ... & Amselem, S. 
(2013). The risk of familial Mediterranean fever in MEFV heterozygotes: a statistical 
approach. PLoS One, 8(7). 
 Kimura, K., Mizooka, M., Migita, K., Ishida, R., Matsumoto, M., Yamasaki, S., ... & Kobayashi, 
T. (2018). Five cases of familial Mediterranean fever in Japan: the relationship with MEFV 
mutations. Internal Medicine, 0057-17. 
 Koné, I. P., Dubuc, M., Sportouch, J., Minodier, P., Garnier, J. M., & Touitou, I. (2000). 
Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high 
frequency of cutaneomucous features. Rheumatology (Oxford, England), 39(11), 1275-1279. 
 Kim, M. L., Chae, J. J., Park, Y. H., De Nardo, D., Stirzaker, R. A., Ko, H. J., ... & Roberts, A. 
W. (2015). Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory 
disease that is dependent on IL-18, not IL-1β. Journal of Experimental Medicine, 212(6), 927-938. 
 Koga, T., Migita, K., Sato, S., Umeda, M., Nonaka, F., Kawashiri, S. Y., ... & Origuchi, T. 
(2016). Multiple Serum Cytokine Profiling to Identify Combinational Diagnostic Biomarkers in 
Attacks of Familial Mediterranean fever. Medicine, 95(16), e3449. 
7
Houri et al.: FAMILIAL MEDITERRANEAN FEVER: A GENERAL REVIEW
Published by Digital Commons @ BAU, 2019
 Kucuksahin, O., et al., (2017). Incidence of sleep disturbances in patients with familial 
Mediterranean fever and the relation of sleep quality with disease activity. International journal of  
rheumatic diseases. 
 Kimura, T., Jain, A., Choi, S. W., Mandell, M. A., Schroder, K., Johansen, T., & Deretic, V. 
(2015). TRIM-mediated precision autophagy targets cytoplasmic regulators of innate 
immunity. Journal of cell biology, 210(6), 973-989. 
 Lee, J. H., Kim, J. H., Shim, J. O., Lee, K. C., Lee, J. W., Lee, J. H., & Chae, J. J. (2016). 
Familial Mediterranean fever presenting as fever of unknown origin in Korea. Korean journal of 
pediatrics, 59(Suppl 1), S53-56. 
 Lofty, H. M., Marzouk, H., Farag, Y., Nabih, M., Khalifa, I. A., Mostafa, N., ... & El Garf, K. 
(2016). Serum amyloid a level in Egyptian children with familial Mediterranean fever. International 
Journal of Rheumatology. 
 Martinon, F., Burns, K., & Tschopp, J. (2002). The inflammasome: a molecular platform 
triggering activation of inflammatory caspases and processing of proIL-β. Molecular cell, 10(2), 
417-426. 
 Makay, B., Kiliçaslan, S. K., Anik, A., Bora, E., Bozkaya, Ö., Çankaya, T., & Ünsal, E. (2017). 
Assessment of sleep problems in children with familial Mediterranean fever. International Journal 
of Rheumatic Diseases, 20(12), 2106-2112. 
 Manukyan, G. P., Ghazaryan, K. A., Ktsoyan, Z. A., Tatyan, M. V., Khachatryan, Z. A., 
Hakobyan, G. S., ... & Aminov, R. I. (2008). Cytokine profile of Armenian patients with familial 
Mediterranean fever. Clinical Biochemistry, 41(10-11), 920-922. 
 Manukyan, G., & Aminov, R. (2016). Update on pyrin functions and mechanisms of familial 
Mediterranean fever. Frontiers in Microbiology, 7, 456. 
 Martinon, F., Hofmann, K., & Tschopp, J. (2001). The pyrin domain: a possible member of the 
death domain-fold family implicated in apoptosis and inflammation. Current Biology, 11(4), R118-
R120. 
 Migita, K., Asano, T., Sato, S., Koga, T., Fujita, Y., & Kawakami, A. (2018). Familial 
Mediterranean fever: overview of pathogenesis, clinical features and management. Immunological 
medicine, 41(2), 55-61. 
 Ostring, G. T., & Singh‐Grewal, D. (2016). Periodic fevers and autoinflammatory syndromes in 
childhood. Journal of paediatrics and child health, 52(9), 865-871. 
 Okutur, K., Seber, S., Oztekin, E., Bes, C., & Borlu, F. (2008). Recurrent pericarditis as the 
initial manifestation of Familial Mediterranean fever. Medical Science Monitor, 14(12), CS139-
CS141. 
 Omenetti, A., Carta, S., Delfino, L., Martini, A., Gattorno, M., & Rubartelli, A. (2014). 
Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: 
correlation with MEFV genotype. Annals of the rheumatic diseases, 73(2), 462-469. 
 Ozdogan, H., & Ugurlu, S. (2019). Familial Mediterranean fever. La Presse Médicale, 48(1), 
e61-e76. 
 Pras, M. (1998). Familial Mediterranean fever: From the Clinical Syndrome to the Cloning of 
the Pyrin Gene: editorial review. Scandinavian journal of rheumatology, 27(2), 92-97. 
 Papin, S., Cuenin, S., Agostini, L., Martinon, F., Werner, S., Beer, H. D., ... & Tschopp, J. 
(2007). The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with 
inflammasome components and inhibits proIL-1 β processing. Cell Death & Differentiation, 14(8), 
1457-1466. 
 Reimann, H.A., (1951). Periodic disease. Medicine, 30(3), 219-45. 
8
BAU Journal - Health and Wellbeing, Vol. 2, Iss. 1 [2019], Art. 5
https://digitalcommons.bau.edu.lb/hwbjournal/vol2/iss1/5
  Reimann, H. A. (1948). Periodic disease: a probable syndrome including periodic fever, benign 
paroxysmal peritonitis, cyclic neutropenia and intermittent arthralgia. Journal of the American 
Medical Association, 136(4), 239-244. 
 Richards, N., Schaner, P., Diaz, A., Stuckey, J., Shelden, E., Wadhwa, A., & Gumucio, D. L. 
(2001). Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced 
apoptosis. Journal of Biological Chemistry, 276(42), 39320-39329. 
 Heilig, R., & Broz, P. (2018). Function and mechanism of the pyrin inflammasome. European 
journal of immunology, 48(2), 230-238. 
 Sönmez, H. E., Batu, E. D., & Özen, S. (2016). Familial Mediterranean fever: current 
perspectives. Journal of inflammation research, 9, 13. 
 Siegal, S. (1945). Benign paroxysmal peritonitis. Annals of internal medicine, 23(1), 1-21. 
 Shohat, M., & Halpern, GJ. (2010). Gene Tests. Familial Mediterranean fever. Retrieved from: 
www.genetests.org. Accessed November 1. 
 Sánchez, F. F., Martinez, M. V., Fernández, A. B., de Lara Martín, I., & Paya, I. E. (2015, 
January). Cardiac tamponade as first manifestation in Mediterranean fever with autosomal dominant 
form. In Anales de pediatria (Barcelona, Spain: 2003) (Vol. 82, No. 1, pp. e82-5). 
 Shohat, M., & Halpern, G. J. (2011). Familial Mediterranean fever—a review. Genetics in 
Medicine, 13(6), 487-498. 
 Soriano, A., & Manna, R. (2012). Familial Mediterranean fever: new phenotypes. Autoimmunity 
reviews, 12(1), 31-37. 
 Seshadri, S., Duncan, M. D., Hart, J. M., Gavrilin, M. A., & Wewers, M. D. (2007). Pyrin levels 
in human monocytes and monocyte-derived macrophages regulate IL-1β processing and 
release. The Journal of Immunology, 179(2), 1274-1281. 
 Tuqan, N. A. (1958). Periodic disease: a clinicopathologic study. Annals of internal 
medicine, 49(4), 885-899. 
 International FMF Consortium. (1997). Ancient missense mutations in a new member of the 
RoRet gene family are likely to cause familial Mediterranean fever. Cell, 90(4), 797-807. 
 Tarantino, G., Esposito, S., Andreozzi, L., Bracci, B., D’Errico, F., & Rigante, D. (2016). Lung 
involvement in children with hereditary autoinflammatory disorders. International journal of 
molecular sciences, 17(12), 2111. 
 Tunca, M., Akar, S., Onen, F., Ozdogan, H., Kasapcopur, O., Yalcinkaya, F., ... & Arici, M. 
(2005). Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter 
study. Medicine, 84(1), 1-11. 
 Touitou, I. (2013). Inheritance of autoinflammatory diseases: shifting paradigms and 
nomenclature. Journal of medical genetics, 50(6), 349-359. 
 Ugurlu, S., Hacioglu, A., Adibnia, Y., Hamuryudan, V., & Ozdogan, H. (2017). Tocilizumab in 
the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean 
fever. Orphanet journal of rare diseases, 12(1), 105. 
 Vajjhala, P. R., Kaiser, S., Smith, S. J., Ong, Q. R., Soh, S. L., Stacey, K. J., & Hill, J. M. 
(2014). Identification of multifaceted binding modes for pyrin and ASC pyrin domains gives 
insights into pyrin inflammasome assembly. Journal of Biological Chemistry, 289(34), 23504-
23519. 
 Varan, O., Kucuk, H., Babaoglu, H., Tecer, D., Atas, N., Bilici Salman, R., ... & Tufan, A. 
(2019). Chronic inflammation in adult familial Mediterranean fever patients: underlying causes and 
association with amyloidosis. Scandinavian journal of rheumatology, 48(4), 315-319. 
 Waite, A. L., Schaner, P., Hu, C., Richards, N., Balci-Peynircioglu, B., Hong, A., ... & Gumucio, 
D. L. (2009). Pyrin and ASC co-localize to cellular sites that are rich in polymerizing 
actin. Experimental Biology and Medicine, 234(1), 40-52. 
9
Houri et al.: FAMILIAL MEDITERRANEAN FEVER: A GENERAL REVIEW
Published by Digital Commons @ BAU, 2019
 Xu, H., Yang, J., Gao, W., Li, L., Li, P., Zhang, L., ... & Wang, F. (2014). Innate immune 
sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature, 513(7517), 
237-241. 
 Yu, J., Wu, J., Zhang, Z., Datta, P., Ibrahimi, I., Taniguchi, S., ... & Alnemri, E. S. (2006). 
Cryopyrin and pyrin activate caspase-1, but not NF-κ B, via ASC oligomerization. Cell Death & 
Differentiation, 13(2), 236-249. 
 Yazılıtaş, F., Aydoğ, Ö., Özlü, S. G., Çakıcı, E. K., Güngör, T., Eroğlu, F. K., ... & Bülbül, M. 
(2018). Canakinumab treatment in children with familial Mediterranean fever: report from a single 
center. Rheumatology international, 38(5), 879-885. 
 Zadeh, N., Getzug, T., & Grody, W. W. (2011). Diagnosis and management of familial 
Mediterranean fever: integrating medical genetics in a dedicated interdisciplinary clinic. Genetics in 
medicine, 13(3), 263-269. 
 Zemer, D., Revach, M., Pras, M., Modan, B., Schor, S., Sohar, E., & Gafni, J. (1974). A 
controlled trial of colchicine in preventing attacks of familial Mediterranean fever. New England 
Journal of Medicine, 291(18), 932-934. 
 Zemer, D., Pras, M., Sohar, E., Modan, M., Cabili, S., & Gafni, J. (1986). Colchicine in the 
prevention and treatment of the amyloidosis of familial Mediterranean fever. New England Journal 
of Medicine, 314(16), 1001-1005. 
 
10
BAU Journal - Health and Wellbeing, Vol. 2, Iss. 1 [2019], Art. 5
https://digitalcommons.bau.edu.lb/hwbjournal/vol2/iss1/5
